Nampota-Nkomba Nginache, Buchwald Andrea, Nyirenda Osward M, Mkandawire Felix A, Masonga Rhoda, Meja Samuel, Moyo Dominic, Cairo Cristiana, Laufer Miriam K
Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi and Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA.
Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA.
J Acquir Immune Defic Syndr. 2025 Apr 17. doi: 10.1097/QAI.0000000000003685.
We evaluated the relationship between maternal HIV and birth outcomes in pregnant women.
Primary health care facilities in Malawi.
In this prospective cohort study, pregnant women attending their first antenatal care (ANC) visit between 20-36 weeks gestation were categorized by HIV status. Women living with HIV were grouped by HIV viral load at ANC and delivery (detectable >400 copies/mL), CD4+ count at delivery (low <250 cells/mm3), and ART regimen (tenofovir- and efavirenz-based ART). We evaluated low birth weight (LBW, <2500g), preterm birth (PTB, <37 weeks gestation), small for gestational age (SGA, <10th percentile for gestational age), fetal death (pregnancy loss >28 weeks gestation), and perinatal death (<7 days) at delivery using multivariate log-binomial regression.
We enrolled 1208 pregnant women (633 and 575 living with and without HIV, respectively) from 2018-2022. HIV was significantly associated with increased risk of fetal or perinatal death (adjusted risk ratio (aRR) 2.09, 95% CI 1.21, 3.70), LBW (aRR 1.88, 95% CI 1.30, 2.76), and PTB (aRR 1.49, 95% CI ( 1.07, 2.09). The strength of the association with LBW increased with increasing exposure to viral load, with an aRR of 2.35 (1.01, 3.99) for LBW among women with detectable viral loads throughout pregnancy. Low CD4+ count at delivery was associated with LBW. HIV was not significantly associated with SGA. Adverse birth outcomes did not differ by ART regimen.
Maternal HIV infection is a risk factor for adverse birth outcomes and the effect is partially mitigated by viral suppression.
我们评估了孕妇感染艾滋病毒与分娩结局之间的关系。
马拉维的初级卫生保健机构。
在这项前瞻性队列研究中,将妊娠20至36周期间首次接受产前检查(ANC)的孕妇按艾滋病毒感染状况进行分类。感染艾滋病毒的妇女按ANC和分娩时的艾滋病毒病毒载量(可检测>400拷贝/mL)、分娩时的CD4+细胞计数(低<250个细胞/mm³)以及抗逆转录病毒治疗方案(基于替诺福韦和依非韦伦的抗逆转录病毒治疗)进行分组。我们使用多变量对数二项回归评估分娩时的低出生体重(LBW,<2500g)、早产(PTB,<37周妊娠)、小于胎龄儿(SGA,<胎龄第10百分位数)、胎儿死亡(妊娠丢失>28周妊娠)和围产期死亡(<7天)情况。
我们在2018年至2022年期间招募了1208名孕妇(分别有633名和575名感染和未感染艾滋病毒)。艾滋病毒与胎儿或围产期死亡风险增加显著相关(调整风险比(aRR)2.09,95%置信区间1.21,3.70)、低出生体重(aRR 1.88,95%置信区间1.30,2.76)和早产(aRR 1.49,95%置信区间(1.07,2.09))。与低出生体重的关联强度随着病毒载量暴露增加而增强,在整个孕期病毒载量可检测的妇女中,低出生体重的aRR为2.35(1.01,3.99)。分娩时低CD4+细胞计数与低出生体重相关。艾滋病毒与小于胎龄儿无显著关联。不良分娩结局在抗逆转录病毒治疗方案之间无差异。
孕产妇感染艾滋病毒是不良分娩结局的一个危险因素,病毒抑制可部分减轻这种影响。